BioSpace News Archive

Moleculin Biotech, Inc. today announced that the US Food aand Drug Administration (FDA) is allowing the Company’s Investigational New Drug (IND) application to study WP1122 for the treatment of Glioblastoma Multiforme (GBM) to go forward.

Lucid Diagnostics Inc. a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc., announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.

Excess fat accumulation in the liver is detrimental to health and can lead to liver cancer. Given the link between this condition and alcohol consumption, the presence of fatty livers in individuals who don’t consume large amounts of alcohol was termed “non-alcoholic fatty liver disease” or NAFLD in the 1980s.

INmune Bio, Inc.(NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced two poster presentations at the 2021 British Society of Immunology Congress, which was held November 28-December 1, in Edinburgh, UK.

Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic 64Cu SAR-bisPSMA clinical trial in patients with untreated, confirmed prostate cancer, scheduled for radical prostatectomy.

As treatment standards and options evolve towards the use of new medicines to treat medical conditions, the use of many older, affordable generic medicines such as pms-Sodium Cromoglycate 1% nebulizer solution has decreased significantly.

FluxWear, a neuromodulation technology company, announces that it will be demonstrating its first product at the Consumer Electronics Show in Las Vegas on January 5-8, 2022.

IFM Therapeutics (IFM), today announced that IFM Due, an IFM subsidiary company, has extended its collaboration and exclusive option agreement with Novartis to develop immunotherapies that inhibit the cGAS-STING pathway to treat a range of serious inflammatory and autoimmune diseases.

Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors have funded the third tranche of its $28 million Series A financing to support the development of its engineered FGF-1, TTHX1114 products for the regenerative treatment of corneal diseases.

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place December 6 - 9 in Charleston, S.C.